Research progress in the systemic treatment of advanced intrahepatic cholangiocarcinomas

Chen Shude; Lin Yipeng; Xu Weihua

doi:10.3969/j.issn.1003-5591.2025.01.013

您当前的位置：

首页 >

文章列表页 >

Research progress in the systemic treatment of advanced intrahepatic cholangiocarcinomas

更新时间：2026-11-05

- Research progress in the systemic treatment of advanced intrahepatic cholangiocarcinomas
- J Abdominal Surg Vol. 38, Issue 1, Pages: 70-73(2025)
- 作者机构：
  
  解放军总医院海南医院肝胆外科，海南三亚 572014
- 作者简介：
  
  Chen Shude， Email：chensd425@126.com
- 基金信息：
- DOI：10.3969/j.issn.1003-5591.2025.01.013
  CLC： R735.8
- Published：22 February 2025
- 稿件说明：
移动端阅览
陈书德,林一鹏,徐伟华.晚期肝内胆管癌系统治疗的研究进展[J].腹部外科,2025,38(01):70-73.

Chen Shude,Lin Yipeng,Xu Weihua.Research progress in the systemic treatment of advanced intrahepatic cholangiocarcinomas[J].J Abdominal Surg,2025,38(01):70-73.
陈书德,林一鹏,徐伟华.晚期肝内胆管癌系统治疗的研究进展[J].腹部外科,2025,38(01):70-73. DOI： 10.3969/j.issn.1003-5591.2025.01.013.

Chen Shude,Lin Yipeng,Xu Weihua.Research progress in the systemic treatment of advanced intrahepatic cholangiocarcinomas[J].J Abdominal Surg,2025,38(01):70-73. DOI： 10.3969/j.issn.1003-5591.2025.01.013.

摘要

肝内胆管癌（intrahepatic cholangiocarcinoma，ICC）是最常见的胆道恶性肿瘤，在原发性肝癌中发病率仅次于肝细胞癌。其发病隐匿，进展快，手术切除是唯一能根治的手段。但ICC恶性程度高，早期诊断困难，多数病人发现时处于中晚期无法手术切除，因此其远期生存率低，预后较差，晚期ICC病人5年生存率仅为5%～10%。近年来，全身化疗、肝动脉灌注化疗、肝动脉化疗栓塞在晚期ICC治疗中显示较好效果，靶向及免疫治疗的出现为不可手术切除的ICC带来了新的希望。该文就化疗、局部治疗、放疗、靶向及免疫治疗在晚期ICC中的研究进展进行了综述，以期为晚期ICC治疗提供新思路。

Abstract

Intrahepatic cholangiocarcinoma（ICC） is the most common biliary malignancy， serving as the top 2 primary hepatocellular carcinoma only secondary to hepatocellular carcinoma.Its onset is insidious and progresses rapidly，and surgical resection is the only curable approach.However，ICC is featured by a high degree of malignancy， and difficulty in the early diagnosis， and many patients are found in the middle and advanced stages that cannot be surgically treated. Therefore，the long-term survival of ICC is low，showing a poor prognosis，and the 5-year survival of advanced ICC of only 5%-10%.In recent years，systemic chemotherapy，hepatic arterial perfusion chemotherapy，and hepatic arterial chemoembolization have shown good results in ICC treatment.The advent of targeted and immunotherapy has brought a new hope for unresectable ICC.This paper reviewed the research progress of chemotherapy，local therapy，radiotherapy，targeted therapy and immunotherapy in the treatment of advanced ICC，so as to provide new ideas for ICC treatment.

关键词

Keywords

references

科技部传染病防治重大专项课题“病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究”专家组 . 肝内胆管癌外科治疗中国专家共识（2020版）［J ］. 中华消化外科杂志， 2021 ， 20 （ 1 ）： 1 - 15 . DOI： 10.3760/cma.j.cn115610-20201211-00777 http://dx.doi.org/10.3760/cma.j.cn115610-20201211-00777 .

Valle J ， Wasan H ， Palmer DH ， et al . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer ［J］. N Engl J Med ， 2010 ， 362 （ 14 ）： 1273 - 1281 . DOI： 10.1056/NEJMoa0908721 http://dx.doi.org/10.1056/NEJMoa0908721 .

Okusaka T ， Nakachi K ， Fukutomi A ， et al . Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer：a comparative multicentre study in Japan ［J］. Br J Cancer ， 2010 ， 103 （ 4 ）： 469 - 474 . DOI： 10.1038/sj.bjc.6605779 http://dx.doi.org/10.1038/sj.bjc.6605779 .

Grenader T ， Nash S ， Plotkin Y ， et al . Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer：the ABC-02 and BT-22 studies ［J］. Ann Oncol ， 2015 ， 26 （ 9 ）： 1910 - 1916 . DOI： 10.1093/annonc/mdv253 http://dx.doi.org/10.1093/annonc/mdv253 .

Morizane C ， Okusaka T ， Mizusawa J ， et al . Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer：the FUGA-BT （JCOG1113） randomized phase Ⅲ clinical trial ［J］. Ann Oncol ， 2019 ， 30 （ 12 ）： 1950 - 1958 . DOI： 10.1093/annonc/mdz402 http://dx.doi.org/10.1093/annonc/mdz402 .

Sahai V ， Catalano PJ ， Zalupski MM ， et al . Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma：a phase 2 clinical trial ［J］. JAMA Oncol ， 2018 ， 4 （ 12 ）： 1707 - 1712 . DOI： 10.1001/jamaoncol.2018.3277 http://dx.doi.org/10.1001/jamaoncol.2018.3277 .

Kim ST ， Kang JH ， Lee J ， et al . Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers：a multicenter，open-label，randomized，phase Ⅲ，noninferiority trial ［J］. Ann Oncol ， 2019 ， 30 （ 5 ）： 788 - 795 . DOI： 10.1093/annonc/mdz058 http://dx.doi.org/10.1093/annonc/mdz058 .

Ioka T ， Kanai M ， Kobayashi S ， et al . Randomized phase Ⅲ study of gemcitabine，cisplatin plus S-1 versus gemcitabine，cisplatin for advanced biliary tract cancer （KHBO1401- MITSUBA）［J］. J Hepatobiliary Pancreat Sci ， 2023 ， 30 （ 1 ）： 102 - 110 . DOI： 10.1002/jhbp.1219 http://dx.doi.org/10.1002/jhbp.1219 .

Amini N ， Ejaz A ， Spolverato G ， et al . Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States：a population-based analysis ［J］. J Surg Oncol ， 2014 ， 110 （ 2 ）： 163 - 170 . DOI： 10.1002/jso.23605 http://dx.doi.org/10.1002/jso.23605 .

Edeline J ， Lamarca A ， McNamara MG ， et al . Locoregional therapies in patients with intrahepatic cholangiocarcinoma：a systematic review and pooled analysis ［J］. Cancer Treat Rev ， 2021 ， 99 ： 102258 . DOI： 10.1016/j.ctrv.2021.102258 http://dx.doi.org/10.1016/j.ctrv.2021.102258 .

Kim GH ， Kim PH ， Kim JH ， et al . Thermal ablation in the treatment of intrahepatic cholangiocarcinoma：a systematic review and meta-analysis ［J］. Eur Radiol ， 2022 ， 32 （ 2 ）： 1205 - 1215 . DOI： 10.1007/s00330-021-08216-x http://dx.doi.org/10.1007/s00330-021-08216-x .

Shindoh J . Ablative therapies for intrahepatic cholangiocarcinoma ［J］. Hepatobiliary Surg Nutr ， 2017 ， 6 （ 1 ）： 2 - 6 . DOI： 10.21037/hbsn.2016.09.07 http://dx.doi.org/10.21037/hbsn.2016.09.07 .

Takahashi EA ， Kinsman KA ， Schmit GD ， et al . Thermal ablation of intrahepatic cholangiocarcinoma：safety，efficacy，and factors affecting local tumor progression ［J］. Abdom Radiol （NY）， 2018 ， 43 （ 12 ）： 3487 - 3492 . DOI： 10.1007/s00261-018-1656-3 http://dx.doi.org/10.1007/s00261-018-1656-3 .

Gairing SJ ， Thol F ， Müller L ， et al . The addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma ［J］. J Clin Med ， 2021 ， 10 （ 12 ）： 2732 . DOI： 10.3390/jcm10122732 http://dx.doi.org/10.3390/jcm10122732 .

Martin RCG ， Simo KA ， Hansen P ， et al . Drug-eluting bead，irinotecan therapy of unresectable intrahepatic cholangiocarcinoma （DELTIC） with concomitant systemic gemcitabine and cisplatin ［J］. Ann Surg Oncol ， 2022 ， 29 （ 9 ）： 5462 - 5473 . DOI： 10.1245/s10434-022-11932-3 http://dx.doi.org/10.1245/s10434-022-11932-3 .

Jiang N ， Zhang Z ， Yin X ， et al . Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma：a multicenter retrospective cohort study ［J］. Radiol Med ， 2024 ， 129 （ 4 ）： 631 - 642 . DOI： 10.1007/s11547-024-01781-3 http://dx.doi.org/10.1007/s11547-024-01781-3 .

Boehm LM ， Jayakrishnan TT ， Miura JT ， et al . Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma ［J］. J Surg Oncol ， 2015 ， 111 （ 2 ）： 213 - 220 . DOI： 10.1002/jso.23781 http://dx.doi.org/10.1002/jso.23781 .

Konstantinidis IT ， Groot Koerkamp B ， Do RKG ， et al . Unresectable intrahepatic cholangiocarcinoma：systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone ［J］. Cancer ， 2016 ， 122 （ 5 ）： 758 - 765 . DOI： 10.1002/cncr.29824 http://dx.doi.org/10.1002/cncr.29824 .

Chakravarty R ， Dash A ， Pillai MR . Availability of yttrium-90 from strontium-90：a nuclear medicine perspective ［J］. Cancer Biother Radiopharm ， 2012 ， 27 （ 10 ）： 621 - 641 . DOI： 10.1089/cbr.2012.1285 http://dx.doi.org/10.1089/cbr.2012.1285 .

Al-Adra DP ， Gill RS ， Axford SJ ， et al . Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization：a systematic review and pooled analysis ［J］. Eur J Surg Oncol ， 2015 ， 41 （ 1 ）： 120 - 127 . DOI： 10.1016/j.ejso.2014.09.007 http://dx.doi.org/10.1016/j.ejso.2014.09.007 .

Edeline J ， Touchefeu Y ， Guiu B ， et al . Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma：a phase 2 clinical trial ［J］. JAMA Oncol ， 2020 ， 6 （ 1 ）： 51 - 59 . DOI： 10.1001/jamaoncol.2019.3702 http://dx.doi.org/10.1001/jamaoncol.2019.3702 .

Schaarschmidt BM ， Kloeckner R ， Dertnig T ， et al . Real-life experience in the treatment of intrahepatic cholangiocarcinoma by 90 radioembolization：a multicenter retrospective study ［J］. J Nucl Med ， 2023 ， 64 （ 4 ）： 529 - 535 . DOI： 10.2967/jnumed.122.264598 http://dx.doi.org/10.2967/jnumed.122.264598 .

Edeline J ， Bridgewater J ， Campillo-Gimenez B ， et al . Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma：data from clinical trials ［J］. Hepatology ， 2024 ， 79 （ 1 ）： 96 - 106 . DOI： 10.1097/HEP.0000000000000544 http://dx.doi.org/10.1097/HEP.0000000000000544 .

Zhang SJ ， Hu P ， Wang N ， et al . Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma ［J］. Ann Surg Oncol ， 2013 ， 20 （ 11 ）： 3596 - 3602 . DOI： 10.1245/s10434-013-3035-1 http://dx.doi.org/10.1245/s10434-013-3035-1 .

Xu CJ ， Li L ， Xu W ， et al . Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma：intermediate-term results ［J］. Int J Hyperthermia ， 2019 ， 36 （ 1 ）： 351 - 358 . DOI： 10.1080/02656736.2019.1571247 http://dx.doi.org/10.1080/02656736.2019.1571247 .

Yang HC ， Cheng ZG ， Han ZY ， et al . Assessment of the outcomes of intrahepatic cholangiocarcinoma after ultrasound-guided percutaneous microwave ablation based on albumin-bilirubin grade ［J］. Cardiovasc Intervent Radiol ， 2021 ， 44 （ 2 ）： 261 - 270 . DOI： 10.1007/s00270-020-02637-9 http://dx.doi.org/10.1007/s00270-020-02637-9 .

Kim YI ， Park JW ， Kim BH ， et al . Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma ［J］. Radiat Oncol ， 2013 ， 8 （ 1 ）： 292 . DOI： 10.1186/1748-717X-8-292 http://dx.doi.org/10.1186/1748-717X-8-292 .

Valle JW ， Lamarca A ， Goyal L ， et al . New horizons for precision medicine in biliary tract cancers ［J］. Cancer Discov ， 2017 ， 7 （ 9 ）： 943 - 962 . DOI： 10.1158/2159-8290.CD-17-0245 http://dx.doi.org/10.1158/2159-8290.CD-17-0245 .

Roy S ， Glaser S ， Chakraborty S . Inflammation and progression of cholangiocarcinoma：role of angiogenic and lymphangiogenic mechanisms ［J］. Front Med ， 2019 ， 6 ： 293 . DOI： 10.3389/fmed.2019.00293 http://dx.doi.org/10.3389/fmed.2019.00293 .

Cai CP ， Wang XJ ， Fu QR ， et al . The VEGF expression associated with prognosis in patients with intrahepatic cholangiocarcinoma：a systematic review and meta-analysis ［J］. World J Surg Oncol ， 2022 ， 20 （ 1 ）： 40 . DOI： 10.1186/s12957-022-02511-7 http://dx.doi.org/10.1186/s12957-022-02511-7 .

Iyer RV ， Pokuri VK ， Groman A ， et al . A multicenter phase Ⅱ study of gemcitabine，capecitabine，and bevacizumab for locally advanced or metastatic biliary tract cancer ［J］. Am J Clin Oncol ， 2018 ， 41 （ 7 ）： 649 - 655 . DOI： 10.1097/COC.0000000000000347 http://dx.doi.org/10.1097/COC.0000000000000347 .

Abou-Alfa GK ， Macarulla T ， Javle MM ， et al . Ivosidenib in IDH1-mutant，chemotherapy-refractory cholangiocarcinoma （ClarIDHy）：a multicentre，randomised，double-blind，placebo-controlled，phase 3 study ［J］. Lancet Oncol ， 2020 ， 21 （ 6 ）： 796 - 807 . DOI： 10.1016/S1470-2045（20）30157-1 http://dx.doi.org/10.1016/S1470-2045（20）30157-1 .

Casak SJ ， Pradhan S ， Fashoyin-Aje LA ， et al . FDA approval summary：ivosidenib for the treatment of patients with advanced unresectable or metastatic，chemotherapy refractory cholangiocarcinoma with an IDH1 mutation ［J］. Clin Cancer Res ， 2022 ， 28 （ 13 ）： 2733 - 2737 . DOI： 10.1158/1078-0432.CCR-21-4462 http://dx.doi.org/10.1158/1078-0432.CCR-21-4462 .

Abou-Alfa GK ， Sahai V ， Hollebecque A ， et al . Pemigatinib for previously treated locally advanced/metastatic chol angiocarcinoma（CCA）：update of FIGHT-202 ［J］. J Clin Oncol ， 2021 ， 39 （ 15_suppl ）： 4086 . DOI： 10.1200/JCO.2021.3 9.15_suppl.4086 http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.4086 .

马世辉，崔云甫 . 肝内胆管癌的分型及综合治疗现状［J］. 腹部外科， 2024 ， 37 （ 3 ）： 161 - 168 . DOI： 10.3969/j.issn.1003-5591.2024.03.002 http://dx.doi.org/10.3969/j.issn.1003-5591.2024.03.002 .

Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy ［J］. Nat Rev Cancer ， 2012 ， 12 （ 4 ）： 252 - 264 . DOI： 10.1038/nrc3239 http://dx.doi.org/10.1038/nrc3239 .

Oh DY ， Chen LT ， He AR ， et al . A phase Ⅲ，randomized，double-blind，placebo-controlled，international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers：topaz-1 ［J］. Ann Oncol ， 2019 ，30：v319. DOI： 10.1093/annonc/mdz247.157 http://dx.doi.org/10.1093/annonc/mdz247.157 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress in triplet therapy for advanced biliary tract cancers

Challenges and prospects for treating biliary tract cancer in the era of targeted therapy and immunotherapy

Advances in immunotherapy for biliary malignancies

Role and mechanism of Nup43 in the proliferation and metastasis of intrahepatic cholangiocarcinoma

The immune microenvironment of cholangiocarcinoma and advances in immunotherapy

Related Author

Leng Kaiming

Shi Guangjun

Yu Liqin

Wang Jian

Zhang Zhengyu

Ma Shihui

Li Shuang

Cui Yunfu

Related Institution

Department of Hepatobiliary Surgery，Qingdao Hospital of University of Health and Rehabilitation Sciences；Qingdao Municipal Hospital

Department of Hepatobiliary and Pancreatic Surgery， Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Department of General Surgery， the 2nd Affiliated Hospital of Harbin Medical University

Department of Hepatobiliary Surgery， Dianjiang County People's Hospital

Department of Hepatobiliary Surgery， the Second Affiliated Hospital of Chongqing Medical University

AI问答

⁰